(Medical Xpress)—Active surveillance of men with low-risk prostate cancer may be better for quality of life and is cost-effective compared with immediate treatment, reports a study published today in CMAJ Open.
Prostate cancer is the most common cancer in Canadian men and the third leading cause of death from cancer. The incidence of prostate cancer, and associated economic costs, has increased 50% over the last three decades, although most cases are low to intermediate risk. Many cancers, despite being low-risk of progressing, are treated and overtreatment can affect patient quality of life.
"Despite published guideline recommendations, overtreatment of prostate cancer is common in the US and elsewhere, with approximately 70% to 90% undergoing active treatments," writes lead author Dr. Alice Dragomir from the Research Institute of the McGill University Health Centre (RI-MUHC) and assistant professor in the Department of Surgery, Division of Urology at McGill University, Montreal, Quebec. "In Canada, approximately 75% of patients with prostate cancer have received active treatment from 1995 through 2002. It is believed today that more than half of these patients did not require active treatment at the time of diagnosis but they incurred cost and morbidity."
Researchers developed a model to estimate cancer costs for active surveillance – watching and waiting to see if cancer progresses – and immediate treatment of patients in Quebec, Canada. They found that active surveillance with follow up over 5 years could save approximately $96 million at the national level as the high-cost of treating cancer that was at low-risk of progressing could be avoided. With active surveillance, the cost per patient for the first year and the subsequent 5 years of follow up was estimated at $6 200 compared with $13, 735 for immediate treatment.
"Our study demonstrates that for eligible patients, active surveillance could offer not only the known clinical advantages from the patient's perspective, but also economic benefits from the health care system perspective," adds senior author Dr. Armen Aprikian, MUHC Chief of Oncology and head of the Division of Urology at McGill University
"The results of our study add to the economic rationale advocating active surveillance for eligible men with low-risk prostate cancer and highlights cost savings estimates specific to the Canadian public system," the authors conclude.
Explore further: Study finds prostate cancer tests underestimate disease in half of cases
More information: Alice Dragomir, Fabio L. Cury, and Armen G. Aprikian. "Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison." CMAJ Open 2:E60-E68; published online April 24, 2014, DOI: 10.9778/cmajo.20130037
Medical Xpress on facebook
Related Stories
Study finds prostate cancer tests underestimate disease in half of cases
Apr 11, 2014
A study published in the British Journal of Cancer suggests that tests to grade and stage prostate cancer underestimated the severity of the disease in half of men whose cancers had been classified as 'sl ...
Active surveillance cost-effective for prostate cancer
Jul 13, 2012
(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, ...
Quarter of prostate cancer patients may abandon 'watchful waiting' approach
Apr 17, 2014
(HealthDay)—Doctors often recommend no treatment at all when a man is diagnosed with prostate cancer, opting instead to keep a close eye on the slow-growing tumor and acting only when it becomes aggressive.
Implications of very low risk prostate cancer assessed
Sep 20, 2013
(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...
Model confirms active surveillance as viable option for men with low-risk prostate cancer
Sep 24, 2012
A new research model has estimated that the difference in prostate cancer mortality among men with low-risk disease who choose active surveillance versus those who choose immediate treatment with radical prostatectomy is ...
Recommended for you
Mayo Clinic launches 50-gene cancer panel test
17 hours ago
Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor. CANCP, an abbreviation for Solid ...
Imaging gives clearer picture of cancer drugs' chances of success
19 hours ago
The quest for new cancer treatments could be revolutionised by advances in technology that can visualise living cells and tissues, scientists claim.
Researchers identify mechanism of cancer caused by loss of BRCA1 and BRCA2 gene function
19 hours ago
Inherited mutations in the BRCA1 or BRCA2 tumor suppressor genes are by far the most frequent contributors to hereditary cancer risk in the human population, often causing breast or ovarian cancer in young women of child-bearing ...
Breast cancer patients place huge emphasis on gene expression profiling test
20 hours ago
Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research ...
Clinical trials to investigate prostate cancer treatment
22 hours ago
The way prostate cancer is treated could have a radical re-think as two international clinical trials go ahead.
Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment
Apr 28, 2014
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a peer ...
User comments
© Medical Xpress 2011-2014, Science X network
(Medical Xpress)—Active surveillance of men with low-risk prostate cancer may be better for quality of life and is cost-effective compared with immediate treatment, reports a study published today in CMAJ Open.
Prostate cancer is the most common cancer in Canadian men and the third leading cause of death from cancer. The incidence of prostate cancer, and associated economic costs, has increased 50% over the last three decades, although most cases are low to intermediate risk. Many cancers, despite being low-risk of progressing, are treated and overtreatment can affect patient quality of life.
"Despite published guideline recommendations, overtreatment of prostate cancer is common in the US and elsewhere, with approximately 70% to 90% undergoing active treatments," writes lead author Dr. Alice Dragomir from the Research Institute of the McGill University Health Centre (RI-MUHC) and assistant professor in the Department of Surgery, Division of Urology at McGill University, Montreal, Quebec. "In Canada, approximately 75% of patients with prostate cancer have received active treatment from 1995 through 2002. It is believed today that more than half of these patients did not require active treatment at the time of diagnosis but they incurred cost and morbidity."
Researchers developed a model to estimate cancer costs for active surveillance – watching and waiting to see if cancer progresses – and immediate treatment of patients in Quebec, Canada. They found that active surveillance with follow up over 5 years could save approximately $96 million at the national level as the high-cost of treating cancer that was at low-risk of progressing could be avoided. With active surveillance, the cost per patient for the first year and the subsequent 5 years of follow up was estimated at $6 200 compared with $13, 735 for immediate treatment.
"Our study demonstrates that for eligible patients, active surveillance could offer not only the known clinical advantages from the patient's perspective, but also economic benefits from the health care system perspective," adds senior author Dr. Armen Aprikian, MUHC Chief of Oncology and head of the Division of Urology at McGill University
"The results of our study add to the economic rationale advocating active surveillance for eligible men with low-risk prostate cancer and highlights cost savings estimates specific to the Canadian public system," the authors conclude.
Explore further: Study finds prostate cancer tests underestimate disease in half of cases
More information: Alice Dragomir, Fabio L. Cury, and Armen G. Aprikian. "Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison." CMAJ Open 2:E60-E68; published online April 24, 2014, DOI: 10.9778/cmajo.20130037
Medical Xpress on facebook
Related Stories
Study finds prostate cancer tests underestimate disease in half of cases
Apr 11, 2014
A study published in the British Journal of Cancer suggests that tests to grade and stage prostate cancer underestimated the severity of the disease in half of men whose cancers had been classified as 'sl ...
Active surveillance cost-effective for prostate cancer
Jul 13, 2012
(HealthDay) -- In a theoretical cohort of 120,000 men, selecting active surveillance for prostate cancer results in considerable cost savings at five and 10 years of follow-up, compared with immediate treatment, ...
Quarter of prostate cancer patients may abandon 'watchful waiting' approach
Apr 17, 2014
(HealthDay)—Doctors often recommend no treatment at all when a man is diagnosed with prostate cancer, opting instead to keep a close eye on the slow-growing tumor and acting only when it becomes aggressive.
Implications of very low risk prostate cancer assessed
Sep 20, 2013
(HealthDay)—The risk of adverse findings at surgery for men with very low risk (VLR) prostate cancer is significantly lower than for those with low risk (LR), according to research published in the October ...
Model confirms active surveillance as viable option for men with low-risk prostate cancer
Sep 24, 2012
A new research model has estimated that the difference in prostate cancer mortality among men with low-risk disease who choose active surveillance versus those who choose immediate treatment with radical prostatectomy is ...
Recommended for you
Mayo Clinic launches 50-gene cancer panel test
17 hours ago
Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor. CANCP, an abbreviation for Solid ...
Imaging gives clearer picture of cancer drugs' chances of success
19 hours ago
The quest for new cancer treatments could be revolutionised by advances in technology that can visualise living cells and tissues, scientists claim.
Researchers identify mechanism of cancer caused by loss of BRCA1 and BRCA2 gene function
19 hours ago
Inherited mutations in the BRCA1 or BRCA2 tumor suppressor genes are by far the most frequent contributors to hereditary cancer risk in the human population, often causing breast or ovarian cancer in young women of child-bearing ...
Breast cancer patients place huge emphasis on gene expression profiling test
20 hours ago
Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research ...
Clinical trials to investigate prostate cancer treatment
22 hours ago
The way prostate cancer is treated could have a radical re-think as two international clinical trials go ahead.
Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment
Apr 28, 2014
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a peer ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment